

# Radiation Toxicity - Pipeline Review, H1 2017

<https://marketpublishers.com/r/R703E21B0DEEN.html>

Date: May 2017

Pages: 202

Price: US\$ 2,000.00 (Single User License)

ID: R703E21B0DEEN

## Abstracts

Radiation Toxicity - Pipeline Review, H1 2017

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers

therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).

The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
  - Aeolus Pharmaceuticals Inc
  - Angion Biomedica Corp
  - Atox Bio Ltd
  - BCN Biosciences LLC
  - Bolder Biotechnology Inc
  - Cellerant Therapeutics Inc
  - Cellphire Inc
  - Chrysalis BioTherapeutics Inc
  - Cleveland BioLabs Inc
  - Daiichi Sankyo Company Ltd
  - FirstString Research Inc
  - Foresee Pharmaceuticals LLC
  - Galera Therapeutics Inc
  - Genzyme Corp
  - GNI Group Ltd
  - Humanetics Corp
  - Insys Therapeutics Inc
  - Meabco A/S
  - Neumedicines Inc

Nohla Therapeutics Inc  
Onconova Therapeutics Inc  
Original BioMedicals Co Ltd  
PharmaIN Corp  
Pluristem Therapeutics Inc  
RDD Pharma Ltd  
Reata Pharmaceuticals Inc  
RedHill Biopharma Ltd  
RxBio Inc  
Shuttle Pharmaceuticals LLC  
SK Chemicals Co Ltd  
Soligenix Inc  
Synedgen Inc  
Tonix Pharmaceuticals Holding Corp  
TSRL Inc  
viDA Therapeutics Inc  
Windtree Therapeutics Inc  
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles  
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile  
A-02 - Drug Profile  
AB-103 - Drug Profile  
ABC-294640 - Drug Profile  
AEOL-10171 - Drug Profile  
Aerosurf - Drug Profile  
amifostine - Drug Profile  
amifostine - Drug Profile  
AVMOC-001 - Drug Profile  
BB-3 - Drug Profile  
BBT-007 - Drug Profile  
BBT-015 - Drug Profile  
BBT-018 - Drug Profile  
BBT-059 - Drug Profile  
BCN-057 - Drug Profile  
BIO-300 - Drug Profile  
BMX-001 - Drug Profile  
BPC-2 - Drug Profile  
C-2E2 - Drug Profile  
C-2E5 - Drug Profile  
Cell Therapy for Acute Radiation Syndrome - Drug Profile

cerium oxide - Drug Profile  
CLT-009 - Drug Profile  
Des-Asp Angiotensin 1 - Drug Profile  
DG-3 - Drug Profile  
entolimod - Drug Profile  
EWA-001 - Drug Profile  
Fibrinoplate-S - Drug Profile  
FP-045 - Drug Profile  
Granexin - Drug Profile  
HSJ-0017 - Drug Profile  
JP4-039 - Drug Profile  
LGM-2605 - Drug Profile  
m-2A2 - Drug Profile  
MDY-1001 - Drug Profile  
molgramostim - Drug Profile  
NAS-911 - Drug Profile  
NMIL-121 - Drug Profile  
omaveloxolone - Drug Profile  
ondansetron hydrochloride - Drug Profile  
ondansetron hydrochloride CR - Drug Profile  
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile  
pirfenidone - Drug Profile  
PLXR-18 - Drug Profile  
Preimplantation Factor - Drug Profile  
QR-205 - Drug Profile  
RDD-2007 - Drug Profile  
recilisib sodium - Drug Profile  
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile  
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile  
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile  
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile  
RP-239X - Drug Profile  
RS-9 - Drug Profile  
rusalotide acetate - Drug Profile  
Rx-100 - Drug Profile  
sargramostim - Drug Profile  
SGX-201 - Drug Profile

SGX-202 - Drug Profile

SKI-2162 - Drug Profile

Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile

Small Molecule for Radiation Toxicity - Drug Profile

Small Molecule for Radiation Toxicity 1 - Drug Profile

Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile

SP-3001 - Drug Profile

ST-266 - Drug Profile

ST-7 - Drug Profile

SY-513 - Drug Profile

SYGN-305 - Drug Profile

SYGN-399 - Drug Profile

Thrombosomes - Drug Profile

TNX-701 - Drug Profile

TPO-7630 - Drug Profile

TPO-7640 - Drug Profile

VEDA-1209 - Drug Profile

VTI-1000 Series - Drug Profile

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd.2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Products under Development by Companies, H1 2017 (Contd.2), H1 2017

Products under Development by Companies, H1 2017 (Contd.3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd.1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd.1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1 2017



Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle

Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd.1), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd.2), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

### COMPANIES MENTIONED

Aeolus Pharmaceuticals Inc

Angion Biomedica Corp

Atox Bio Ltd

BCN Biosciences LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Cellphire Inc

Chrysalis BioTherapeutics Inc

Cleveland BioLabs Inc

Daiichi Sankyo Company Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Galera Therapeutics Inc

Genzyme Corp

GNI Group Ltd

Humanetics Corp

Insys Therapeutics Inc

Meabco A/S

Neumedicines Inc

Nohla Therapeutics Inc

Onconova Therapeutics Inc  
Original BioMedicals Co Ltd  
PharmaIN Corp  
Pluristem Therapeutics Inc  
RDD Pharma Ltd  
Reata Pharmaceuticals Inc  
RedHill Biopharma Ltd  
RxBio Inc  
Shuttle Pharmaceuticals LLC  
SK Chemicals Co Ltd  
Soligenix Inc  
Synedgen Inc  
Tonix Pharmaceuticals Holding Corp  
TSRL Inc  
viDA Therapeutics Inc  
Windtree Therapeutics Inc

## I would like to order

Product name: Radiation Toxicity - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/R703E21B0DEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R703E21B0DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970